Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Additional Information (Details)

v3.23.1
Summary of Significant Accounting Policies - Additional Information (Details)
 12 Months Ended
Sep. 17, 2021
shares
Aug. 11, 2021
$ / shares
shares
Jan. 06, 2021
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
segment
consultant
director
vendor
shares
Dec. 31, 2021
USD ($)
consultant
university
vendor
shares
Accounting Policies [Line Items]          
Restricted cash       $ 49,260 $ 45,000
Tangible asset impairment       0  
Goodwill       0 0
Impairment loss on goodwill       0 4,037,811
In-process R&D       $ 10,600,000 10,600,000
Business segment | segment       1  
Geographic segments | segment       3  
Deferred tax liabilities       $ 689,121 802,131
Unrecognized uncertain income tax       0 0
Tax receivable       $ 1,300,000 $ 500,000
Unvested restricted common stock (in shares) | shares       30,000 375
Number of vendors with whom the company has entered into related party transactions | vendor       1 1
Number of consultants with whom the company has entered into related party transactions | consultant       6 6
Director who Is also an executive at a related party | director       1  
Number of universities with whom the company entered into related party transactions | university         2
Shares issued (in shares) | shares 273 116,721 38,278    
Warrants to purchase common stock (in shares) | shares   5,836      
Purchase price (in usd per share) | $ / shares   $ 92.10      
Net proceeds from the private placement     $ 8,000,000    
Increase (decrease) in contingent consideration       $ 582,605 $ (475,956)
Other assets or liabilities that are subject to fair value methodology and estimation       0 0
Clinical Studies Services KIO-301 | Affiliated Entity          
Accounting Policies [Line Items]          
Expenses from transactions with related party       100,000  
Due to related parties included in accounts payable       $ 100,000  
Common Stock | Private Placement | Affiliated Entity          
Accounting Policies [Line Items]          
Shares issued (in shares) | shares     38,278    
Warrants to purchase common stock (in shares) | shares     38,278    
Purchase price (in usd per share) | $ / shares     $ 209.00    
Net proceeds from the private placement     $ 8,000,000    
Minimum          
Accounting Policies [Line Items]          
Estimated useful life       2 years  
Maximum          
Accounting Policies [Line Items]          
Estimated useful life       5 years  
Bayon acquisition          
Accounting Policies [Line Items]          
Fair value of contingent consideration       $ 1,100,000 900,000
Increase (decrease) in contingent consideration       300,000  
Panoptes acquisition          
Accounting Policies [Line Items]          
Fair value of contingent consideration       1,700,000 1,600,000
Increase (decrease) in contingent consideration       100,000  
Jade acquisition          
Accounting Policies [Line Items]          
Fair value of contingent consideration       700,000 $ 600,000
Increase (decrease) in contingent consideration       $ 200,000